Pink Sheet reporters and editor discuss a projected list of drugs that could be eligible for the first round of Medicare price negotiations (:40), the future of mifepristone access after the latest court decision (9:24), and AstraZeneca receiving the first US FDA drug promotion warning letter in more than a year (21:55). More On These Topics From The Pink Sheet Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It: https://pink.pharmaintelligence.informa.com/PS148718/Medicare-Price-Negotiation-List-Remains-A-Puzzle-Even-For-Those-That-Are-Probably-On-It Mifepristone REMS Modifications Likely Violated Administrative Procedure Act, Appeals Court Says: https://pink.pharmaintelligence.informa.com/PS148721/Mifepristone-REMS-Modifications-Likely-Violated-Administrative-Procedure-Act-Appeals-Court-Says Breaking Down The Arguments In The Mifepristone Case: https://pink.pharmaintelligence.informa.com/PS148678/Breaking-Down-The-Arguments-In-The-Mifepristone-Case The Mifepristone Story So Far: Tracing The Origins Of The Legal Fight Over The Abortion Pill: https://pink.pharmaintelligence.informa.com/PS148679/The-Mifepristone-Story-So-Far-Tracing-The-Origins-Of-The-Legal-Fight-Over-The-Abortion-Pill AstraZeneca Gets Rare Warning Letter Over Breztri Sales Aid; Footnotes Don’t Balance Graphics: https://pink.pharmaintelligence.informa.com/PS148710/AstraZeneca-Gets-Rare-Warning-Letter-Over-Breztri-Sales-Aid-Footnotes-Dont-Balance-Graphics

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related